Cyclic AMP-mediated signal transduction in heart failure: Molecular pathophysiology and therapeutic implications

Journal of Investigative Medicine

Volumn 45, Issue 8, 1997, Pages 432-440

  Movsesian, Matthew A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE;

ANIMAL; CONGESTIVE HEART FAILURE; HEART MUSCLE; HUMAN; HYDROLYSIS; METABOLISM; MUSCLE CONTRACTION; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEART FAILURE, CONGESTIVE; HUMANS; HYDROLYSIS; MUSCLE CONTRACTION; MYOCARDIUM; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 0031252968     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-9.
2. Goldberg LI, Hsieh Y-Y, Resnekov L. Newer catecholamines for treatment of heart failure and shock: an update on dopamine and dobutamine. Prog Cardiovasc Dis 1977;19:327-40.
3. Colucci WS. Positive inotropic/vasodilator agents. Cardiol Clin 1989;7:131-44.
4. Chatterjee K. Newer oral inotropic agents: phosphodiesterase inhibitors. Crit Care Med 1990;18:S34-8.
5. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet 1993;342:1441-6
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med 1996;334:1349-55.
7. Benovic JL, Bouvier M, Caron MG, Lefkowitz RJ. Regulation of adenylyl cyclase-coupled β-adrenergic receptors. Annu Rev Cell Biol 1988;4:405-28.
8. Goodman AG. Nobel Lecture. G proteins and regulation of adenylyl cyclase. Biosci Rep 1995;15: 65-97.
9. Ichikawa A, Sugimoto Y, Negishi M. Molecular aspects of the structures and functions of the prostaglandin E receptors. J Lipid Mediat Cell Signal 1996;14:83-7.
10. Negishi M, Irie A, Sugimoto Y, Namba T, Ichikawa A. Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J Biol Chem 1995;270:16122-7.
11. Negishi M, Ito S, Hayaishi O. Prostaglandin E receptors in bovine adrenal medulla are coupled to adenylate cyclase via Gi and to phosphoinositide metabolism in a pertussis toxin-insensitive manner. J Biol Chem 1989;264:3916-23.
12. Freissmuth M, Casey PJ, Gilman AG. G proteins control diverse pathways of transmembrane signaling. FASEB J 1989;3:2125-31.
13. Hepler JR, Gilman AG. G proteins. Trends Biochem Sci 1992;17: 383-7.
14. Spiegel AM. Signal transduction by guanine nucleotide binding proteins. Mol Cell Endocrinol 1987;49:1-16.
15. 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem 1995;270:17953-61.
16. Benovic JL, Pike LJ, Cerione RA, Staniszewski C, Yoshimasa T, Codina J, Caron MG, Lefkowitz RJ. Phosphorylation of the mammalian β-adrenergic receptor by cyclic AMP-dependent protein kinase. Regulation of the rate of receptor phosphorylation and dephosphorylation by agonist occupancy and effects on coupling of the receptor to the stimulatory guanine nucleotide regulatory protein. J Biol Chem 1985;260:7094-101.
17. Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. β-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci USA 1986;83:2797-801.
18. Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ. β-arrestin: a protein that regulates β-adrenergic receptor function. Science 1990;248:1547-50.
19. Lefkowitz RJ, Inglese J, Koch WJ, Pitcher J, Attramadal H; Caron MG. G-protein-coupled receptors: regulatory role of receptor kinases and arrestin proteins. Cold Spring Harb Symp Quant Biol 1992;57:127-33.
20. Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Menard L, Caron MG. Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 1996;271:363-6.
21. 2-adrenergic receptors permit receptor resensitization. Mol Pharmacol 1995;47:666-76.
22. Yu SS, Lefkowitz RJ, Hausdorff WP. β-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. J Biol Chem 1993;268:337-41.
23. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, Van Dop C. Increase in the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988;82:189-97.
24. iα in human heart with dilated but not ischemic cardiomyopathy. Circulation 1990;82:1249-65.
25. 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-63.
26. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
27. 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
28. 2-adrenergic receptor-mediated adenylate cyclase stimula-tion in nonfailing and failing human ventricular myocardium. Mol Pharm 1989;35:295-303.
29. Mickey J, Tate R, Lefkowitz RJ. Subsensitivity of adenylate cyclase and decreased β-adrenergic receptor binding after chronic exposure to (-)-isoproterenol in vitro. J Biol Chem 1975;250:5727-9.
30. Homburger V, Lucas M, Cantau B, Barabe J, Penit J, Bockaert J. Further evidence that desensitization of β-adrenergic sensitive adenylate cyclase proceeds in two steps. J Biol Chem 1980;255:10436-44.
31. Limas CJ, Limas C. Rapid recovery of cardiac β-adrenergic receptors after isoproterenol-induced downregulation. Circ Res 1984;55:524-31.
32. Sigmund M, Jakob H, Backer H, Hanrath P, Schumacher C, Eschenhagen T, Schmitz W, Scholz H, Steinfath M. Effects of metoprolol on myocardial β-adrenoceptors and Gi alpha-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 1996;51:127-32.
33. Bristow MR, Ginsburg R, Strosberg A, Montgomery W, Minobe W. Pharmacology and inotropic potential of forskolin in the human heart. J Clin Invest 1984;74:212-23.
34. s-stimulated adenylyl cyclases. FASEB J 1993;7:768-75.
35. Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 1996;36:461-80.
36. Komas N, Movsesian M, Kedev S, Degerman E, Belfrage P and Manganiello VC. cGMP-inhibited cyclic nucleotide phosphodiesterases. In: Schudt C, Dent G, Rabe KF, eds. Phosphodiesterase inhibitors. San Diego: Academic Press, 1996:89-109.
37. Benotti J, Grossman W, Braunwald E, Davolos D, Alousi A. Hemodynamic assessment of amrinone: a new inotropic agent. N Engl J Med 1978;299:1373-7.
38. Alousi A, Farah A, Lesher G, Opalka J. Cardiotonic activity of amrinone-Win 40680 [5-amino,3′,4′-bipyredin-6(1H)-one]. Circ Res 1979;55:666-77.
39. Honerjäger P, Schafer-Korting M, Reiter M. Involvement of cyclic AMP in the direct inotropic action of amrinone: biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol 1981;318:112-20.
40. Dage RC, Roebel LE, Hsieh C-P, Weiner DL, Woodward JK. Cardiovascular properties of a new cardiotonic agent MDL 17,043 (1,3 dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imadazol-2-one). J Cardiovasc Pharmacol 1982;4:500-8.
41. Roebel LE, Dage RC, Cheng HC, Woodward JK. In vitro and in vivo assessment of the cardiovascular effects of the cardiotonic drug MDL 19205. J Cardiovasc Pharmacol 1984;6:43-9.
42. Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to β-adrenoceptor downregulation. J Cardiovasc Pharmacol 1988;12:726-32.
43. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991;88:15-9.
44. Gilbert EM, Hershberger RE, Wiechman RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined β-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 1995;108:1524-32.
45. Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, Braunwald E, Grossman W. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 1983;309:748-56.
46. Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, LeJemtel TH. Long-term therapy with a new cardiotonic agent, WIN 47203: Drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983;2:327-31.
47. Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP. The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure. Circulation 1983;67:823-8.
48. DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984;4:855-66.
49. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest 1985;75:643-9.
50. Massie B, Bourassa M, DiBianco R, Hess M, Konstam M, Likoff M, Packer M. Long- term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963-71.
51. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989;320:677-83.
52. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S, Herrmann HC, Sandberg JA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774-80.
53. Nony P, Boissel J-P, Lièvre M, Leizorovicz A, Haugh MC, Fareh S, de Breyne B. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. Eur J Clin Pharmacol 1994;46:191-6.
54. 1. J Biol Chem 1980;255:5113-9.
55. Buxton IL, Brunton LL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 1983;258:10233-9.
56. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem 1994;269:19151-6.
57. 2-adrenoceptor agonists in guinea pig hearts. J Cardiovasc Pharmacol 1995;26:893-8.
58. 2+ transients. Circulation 1991;69:1369-79.
59. 2+ current in single rat ventricular cells. Circ Res 1993;73:286-300.
60. Exton JH. Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab Rev 1987;3:163-83.
61. Habener JF. Cyclic AMP response element binding proteins: a cornucopia of transcription factors. Mol Endocrinol 1990;4:1087-94.
62. Böhm M, Reiger B, Schwinger RHG, Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 1994;28:1713-9.
63. m,cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 1993;190:516-21.
64. Taylor SS, Buechler JA, Yonemoto W. cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 1990;59:971-1005.
65. Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther 1991;50:123-45.
66. Johnson DA, Leathers VL, Martinez AM, Walsh DA, Fletcher WH. Fluorescence resonance energy transfer within a heterochromatic cAMP-dependent protein kinase holoenzyme under equilibrium conditions: new insights into the conformational changes that result in cAMP-dependent activation. Biochemistry 1993;32:6402-10.
67. Corbin JD, Sugden PH, Lincoln TM, Keely SL. Compartmentalization of adenosine 3′:5′-monophosphate and adenosine 3':5'monophosphate-dependent protein kinase in heart tissue. J Biol Chem 1977;252:3854-61.
68. Leiser M, Rubin CS, Erlichman J. Differential binding of the regulatory subunits (RII) of cAMP-dependent protein kinase II from bovine brain and muscle to RII-binding proteins. J Biol Chem 1986;261:1904-8.
69. Coghlan VM, Bergeson SE, Langeberg L, Nilaver G, Scott JD. A-Kinase anchoring proteins: a key to selective activation of cAMP-responsive events? Mol Cell Biochem 1993;127/128:309-19.
70. Robinson ML, Wallert MA, Reinitz CA, Shabb JB. Association of the type I regulatory subunit of cAMP-dependent protein kinase with cardiac myocyte sarcolemma. Arch Biochem Biophys 1996;330:181-7.
71. Ogreid D, Ekanger R, Silva RH, Miller JP, Døskeland SO. Comparison of the two classes of binding sites (A and B) of type I and type II cyclic-AMP-dependent protein kinases by using cyclic nucleotide analogs. Eur J Biochem 1989;181:19-31.
72. Dostmann WRG, Taylor SS, Genieser H-G, Jastorff B, Døskeland SO, Ogreid D. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem 1990;265:10484-91.
73. Gjertsen BT, Mellgren G, Otten A, Maronde E, Genieser HG, Jastorff B, Vintermyr OK, McKnight GS, Døskeland SO. Novel (Rp)-cAMPS analogs as tools for inhibition of cAMP-kinase in cell culture. J Biol Chem 1995;270: 20599-607.
74. Skålhegg BS, Landmark BF, Døskeland SO, Hansson V, Lea T, Jahnsen T. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem 1992;267:15707-14.
75. Laxminarayana D, Berrada A, Kammer GM. Early events of human T lymphocyte activation are associated with type I protein kinase A activity. J Clin Invest 1993;92: 2207-14.
76. Sculptoreanu A, Rotman E, Takahashi M, Scheuer T, Catterall WA. Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc Natl Acad Sci USA 1993;90:10135-9.
77. De Jongh KS, Murphy BJ, Colvin AA, Hell JW, Takahashi M, Catterall WA. Specific phosphorylation of a site in the full-length form of the alpha 1 subunit of the cardiac L-type calcium channel by adenosine 3′,5′-cyclic monophosphate-dependent protein kinase. Biochemistry 1996;35:10392-402
78. Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem 1991;266:11144-52.
79. Hain J, Onoue H, Mayrleitner M, Fleischer S, Schindler H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J Biol Chem 1995;270:2074-81.
80. Solaro RJ, Robertson SP, Johnson JD, Holroyde MJ, Potter JD. Troponin-I phosphorylation: a unique regulator of the amount of calcium required to activate cardiac myofibrils. Cold Spring Harb Conf Cell Proliferation 1981;8:901-11.
81. 2+ transport as studied by reconstitution of cardiac sarcoplasmic reticulum. J Biol Chem 1986;261:1794-1800.
82. 2+ pump of the sarcoplasmic reticulum. Nature 1989;342:90-2.
83. 2+ pump ATPase. J Biol Chem 1992;267:1674-9.
84. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Dufy JJ, Doetschman T, Kranias EG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of -agonist stimulation. Circ Res 1994;75:401-9.
85. Limas CJ, Olivari M-T, Goldenberg IF, Levine TB, Benditt DG, Simon A. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 1987;21:601-5.
86. 2+-ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434-42.
87. 2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995;92:3220-8.
88. Flesch M, Schwinger RH, Schnabel P, Schiffer F, van Gelder I, Bavendiek U, Sudkamp M, Kuhn-Regnier F, Böhm M. Sarcoplasmic reticulum Ca2+ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med 1996;74:321-32.
89. 2+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-53.
90. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-84.
91. 2+ uptake in sarcoplasmic reticulum from normal and failing hearts. J Clin Invest 1990;85:1698-702.
92. 2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 1996;31:625-32.
93. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991;88:15-9.
94. 2+-transporting ATPase, phospholamban and calsequestrin levels in nonfailing and failing human myocardium. Circulation 1994;90:653-7.
95. 2+ accumulation in nonfailing and failing human myocardium. Circulation 1995;92:2504-10.
96. 2+-ATPase activity of SERCA II in human myocardium [abstract]. Circulation 1996;94:I-673.